Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia.

Wang T, Shatara M, Liu F, Knight T, Edwards H, Wang G, Lin H, Wang Y, Taub JW, Ge Y.

Signal Transduct Target Ther. 2019 Nov 1;4:44. doi: 10.1038/s41392-019-0076-3. eCollection 2019. No abstract available.

2.

Monozygotic twins with neuroblastoma MS have a similar molecular profile: a case of twin-to-twin metastasis.

Shatara M, Xavier AC, Dombkowski A, Cukovic D, Poulik JM, Altinok D, Ge Y, Taub JW.

Br J Cancer. 2019 Nov;121(10):890-893. doi: 10.1038/s41416-019-0594-3. Epub 2019 Oct 11.

PMID:
31601961
3.

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, Metzner M, Kennedy A, Amstislavskiy V, Risch T, Bhayadia R, Samulowski D, Hernandez DC, Stoilova B, Iotchkova V, Oppermann U, Scheer C, Yoshida K, Schwarzer A, Taub JW, Crispino JD, Weiss MJ, Hayashi Y, Taga T, Ito E, Ogawa S, Reinhardt D, Yaspo ML, Campbell PJ, Roberts I, Constantinescu SN, Vyas P, Heckl D, Klusmann JH.

Cancer Cell. 2019 Sep 16;36(3):340. doi: 10.1016/j.ccell.2019.08.014. No abstract available.

PMID:
31526763
4.

Pediatric cancer, posttraumatic stress and fear-related neural circuitry.

Marusak HA, Harper FW, Taub JW, Rabinak CA.

Int J Hematol Oncol. 2019 Jul 11;8(2):IJH17. doi: 10.2217/ijh-2019-0002. Review.

5.

Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.

Mast KJ, Taub JW, Alonzo TA, Gamis AS, Mosse CA, Mathew P, Berman JN, Wang YC, Jones HM, Campana D, Coustan-Smith E, Raimondi SC, Hirsch B, Hitzler JK, Head DR.

Arch Pathol Lab Med. 2019 Aug 20. doi: 10.5858/arpa.2018-0526-OA. [Epub ahead of print]

PMID:
31429606
6.

Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome.

Brown AL, de Smith AJ, Gant VU, Yang W, Scheurer ME, Walsh KM, Chernus JM, Kallsen NA, Peyton SA, Davies GE, Ehli EA, Winick N, Heerema NA, Carroll AJ, Borowitz MJ, Wood BL, Carroll WL, Raetz EA, Feingold E, Devidas M, Barcellos LF, Hansen HM, Morimoto L, Kang AY, Smirnov I, Healy J, Laverdière C, Sinnett D, Taub JW, Birch JM, Thompson P, Spector LG, Pombo-de-Oliveira MS, DeWan AT, Mullighan CG, Hunger SP, Pui CH, Loh ML, Zwick ME, Metayer C, Ma X, Mueller BA, Sherman SL, Wiemels JL, Relling MV, Yang JJ, Lupo PJ, Rabin KR.

Blood. 2019 Oct 10;134(15):1227-1237. doi: 10.1182/blood.2018890764.

PMID:
31350265
7.

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.

Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y.

Clin Cancer Res. 2019 Nov 15;25(22):6815-6826. doi: 10.1158/1078-0432.CCR-19-0832. Epub 2019 Jul 18.

PMID:
31320594
8.

Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.

Labuhn M, Perkins K, Matzk S, Varghese L, Garnett C, Papaemmanuil E, Metzner M, Kennedy A, Amstislavskiy V, Risch T, Bhayadia R, Samulowski D, Hernandez DC, Stoilova B, Iotchkova V, Oppermann U, Scheer C, Yoshida K, Schwarzer A, Taub JW, Crispino JD, Weiss MJ, Hayashi Y, Taga T, Ito E, Ogawa S, Reinhardt D, Yaspo ML, Campbell PJ, Roberts I, Constantinescu SN, Vyas P, Heckl D, Klusmann JH.

Cancer Cell. 2019 Aug 12;36(2):123-138.e10. doi: 10.1016/j.ccell.2019.06.007. Epub 2019 Jul 11. Erratum in: Cancer Cell. 2019 Sep 16;36(3):340.

PMID:
31303423
9.

Heritable variation at the chromosome 21 gene ERG is associated with acute lymphoblastic leukemia risk in children with and without Down syndrome.

de Smith AJ, Walsh KM, Morimoto LM, Francis SS, Hansen HM, Jeon S, Gonseth S, Chen M, Sun H, Luna-Fineman S, Antillón F, Girón V, Kang AY, Smirnov I, Shao X, Whitehead TP, Barcellos LF, Jolly KW, Healy J, Laverdière C, Sinnett D, Taub JW, Birch JM, Thompson PD, Pombo-de-Oliveira MS, Spector LG, DeWan AT, Mueller BA, Chiang C, Metayer C, Ma X, Wiemels JL.

Leukemia. 2019 Nov;33(11):2746-2751. doi: 10.1038/s41375-019-0514-9. Epub 2019 Jul 11. No abstract available.

PMID:
31296947
10.

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia.

Knight T, Edwards H, Taub JW, Ge Y.

Cancer Manag Res. 2019 Apr 23;11:3197-3213. doi: 10.2147/CMAR.S180724. eCollection 2019.

11.

Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.

Liu F, Knight T, Su Y, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Sun L, Ge Y.

Target Oncol. 2019 Jun;14(3):351-364. doi: 10.1007/s11523-019-00638-4.

PMID:
31115744
12.

Understanding differences in the long-term psychosocial adjustment of pediatric cancer patients and their parents: an individual differences resources model.

Harper FWK, Albrecht TL, Trentacosta CJ, Taub JW, Phipps S, Penner LA.

Transl Behav Med. 2019 May 16;9(3):514-522. doi: 10.1093/tbm/ibz025.

PMID:
31094435
13.

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.

Li X, Su Y, Madlambayan G, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Ma J, Knight T, Wang G, Wang Y, Yang J, Taub JW, Lin H, Ge Y.

Haematologica. 2019 Nov;104(11):2225-2240. doi: 10.3324/haematol.2018.201343. Epub 2019 Feb 28.

14.

A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.

Knight T, Luedtke D, Edwards H, Taub JW, Ge Y.

Biochem Pharmacol. 2019 Apr;162:250-261. doi: 10.1016/j.bcp.2019.01.015. Epub 2019 Jan 19. Review.

PMID:
30668936
15.

Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.

Luedtke DA, Su Y, Liu S, Edwards H, Wang Y, Lin H, Taub JW, Ge Y.

J Cell Mol Med. 2018 Dec;22(12):6099-6111. doi: 10.1111/jcmm.13886. Epub 2018 Sep 14.

16.

Emotion-related brain organization and behavioral responses to socioemotional stimuli in pediatric cancer survivors with posttraumatic stress symptoms.

Marusak HA, Iadipaolo AS, Paulisin S, Harper FW, Taub JW, Dulay K, Elrahal F, Peters C, Sala-Hamrick K, Crespo LM, Rabinak CA.

Pediatr Blood Cancer. 2019 Jan;66(1):e27470. doi: 10.1002/pbc.27470. Epub 2018 Sep 30.

17.

Ethosuximide-induced Thrombocytopenia: A Case Report.

Shatara M, Regling K, Sabo C, Figueroa M, Taub JW, Rajpurkar M.

J Pediatr Hematol Oncol. 2019 Jul;41(5):420-421. doi: 10.1097/MPH.0000000000001310. No abstract available.

PMID:
30212418
18.

Clinical Trial Enrollment is Associated With Improved Follow-up Rates Among Survivors of Childhood Cancer.

Hutchins KK, Savaşan S, Thomas RL, Strathdee LA, Wang ZJ, Taub JW.

J Pediatr Hematol Oncol. 2019 Jan;41(1):e18-e23. doi: 10.1097/MPH.0000000000001169.

19.

Incidence and outcomes of rare paediatric non-hodgkin lymphomas.

Sorge C, Costa LJ, Taub JW, S Cairo M, Xavier AC.

Br J Haematol. 2019 Mar;184(5):864-867. doi: 10.1111/bjh.15194. Epub 2018 Apr 2. No abstract available.

PMID:
29611181
20.

Neurodevelopmental consequences of pediatric cancer and its treatment: applying an early adversity framework to understanding cognitive, behavioral, and emotional outcomes.

Marusak HA, Iadipaolo AS, Harper FW, Elrahal F, Taub JW, Goldberg E, Rabinak CA.

Neuropsychol Rev. 2018 Jun;28(2):123-175. doi: 10.1007/s11065-017-9365-1. Epub 2017 Dec 22. Review.

21.

Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.

Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW, Ge Y.

Signal Transduct Target Ther. 2017 Apr 7;2:17012. doi: 10.1038/sigtrans.2017.12. eCollection 2017.

22.

Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo.

Su Y, Li X, Ma J, Zhao J, Liu S, Wang G, Edwards H, Taub JW, Lin H, Ge Y.

Biochem Pharmacol. 2018 Feb;148:13-26. doi: 10.1016/j.bcp.2017.11.022. Epub 2017 Dec 5.

23.

Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.

Xavier AC, Epperla N, Taub JW, Costa LJ.

Am J Hematol. 2018 Feb;93(2):238-245. doi: 10.1002/ajh.24964. Epub 2017 Nov 21.

24.

Mindfulness and dynamic functional neural connectivity in children and adolescents.

Marusak HA, Elrahal F, Peters CA, Kundu P, Lombardo MV, Calhoun VD, Goldberg EK, Cohen C, Taub JW, Rabinak CA.

Behav Brain Res. 2018 Jan 15;336:211-218. doi: 10.1016/j.bbr.2017.09.010. Epub 2017 Sep 5.

25.

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.

Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y.

Oncotarget. 2017 Jul 4;8(27):44295-44311. doi: 10.18632/oncotarget.17869.

26.

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.

Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS.

Blood. 2017 Jun 22;129(25):3304-3313. doi: 10.1182/blood-2017-01-764324. Epub 2017 Apr 7.

27.

Concomitant Use of Panobinostat and Reirradiation in Progressive DIPG: Report of 2 Cases.

Wang ZJ, Ge Y, Altinok D, Poulik J, Sood S, Taub JW, Edwards H, Kieran MW, Steven M.

J Pediatr Hematol Oncol. 2017 Aug;39(6):e332-e335. doi: 10.1097/MPH.0000000000000806.

PMID:
28234741
28.

Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.

Ma J, Li X, Su Y, Zhao J, Luedtke DA, Epshteyn V, Edwards H, Wang G, Wang Z, Chu R, Taub JW, Lin H, Wang Y, Ge Y.

Sci Rep. 2017 Feb 8;7:41950. doi: 10.1038/srep41950.

29.

Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.

Zhao J, Xie C, Edwards H, Wang G, Taub JW, Ge Y.

Oncotarget. 2017 Jan 24;8(4):6319-6329. doi: 10.18632/oncotarget.14062.

30.

Pediatric Cancer Patients' Treatment-Related Distress and Longer-Term Anxiety: An Individual Differences Perspective.

Trentacosta CJ, Harper FW, Albrecht TL, Taub JW, Phipps S, Penner LA.

J Dev Behav Pediatr. 2016 Nov/Dec;37(9):753-761.

31.

Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo.

Schwartz J, Niu X, Walton E, Hurley L, Lin H, Edwards H, Taub JW, Wang Z, Ge Y.

Am J Transl Res. 2016 Sep 15;8(9):3893-3902. eCollection 2016.

32.

Gene Signature of High White Blood Cell Count in B-Precursor Acute Lymphoblastic Leukemia.

Edwards H, Rubenstein M, Dombkowski AA, Caldwell JT, Chu R, Xavier AC, Thummel R, Neely M, Matherly LH, Ge Y, Taub JW.

PLoS One. 2016 Aug 18;11(8):e0161539. doi: 10.1371/journal.pone.0161539. eCollection 2016.

33.

Synthesis and Antileukemic Activities of Piperlongumine and HDAC Inhibitor Hybrids against Acute Myeloid Leukemia Cells.

Liao Y, Niu X, Chen B, Edwards H, Xu L, Xie C, Lin H, Polin L, Taub JW, Ge Y, Qin Z.

J Med Chem. 2016 Sep 8;59(17):7974-90. doi: 10.1021/acs.jmedchem.6b00772. Epub 2016 Aug 24.

34.

Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.

Zhao J, Niu X, Li X, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Ge Y.

Oncotarget. 2016 Jun 7;7(23):34785-99. doi: 10.18632/oncotarget.9185.

35.

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.

Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, Caldwell JT, Xiang S, Zhang X, Chu R, Wang ZJ, Lin H, Taub JW, Ge Y.

Clin Cancer Res. 2016 Sep 1;22(17):4440-51. doi: 10.1158/1078-0432.CCR-15-3057. Epub 2016 Apr 21.

36.

Satisfaction with support versus size of network: differential effects of social support on psychological distress in parents of pediatric cancer patients.

Harper FW, Peterson AM, Albrecht TL, Taub JW, Phipps S, Penner LA.

Psychooncology. 2016 May;25(5):551-8. doi: 10.1002/pon.3863. Epub 2015 Jun 17.

37.

Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.

Qi W, Zhang W, Edwards H, Chu R, Madlambayan GJ, Taub JW, Wang Z, Wang Y, Li C, Lin H, Ge Y.

Cancer Biol Ther. 2015;16(12):1784-93. doi: 10.1080/15384047.2015.1095406.

38.

Posttraumatic Stress Symptoms in Parents of Pediatric Cancer Patients: A Mediational Analysis.

Harper FW, Peterson AM, Albrecht TL, Taub JW, Phipps S, Penner LA.

J Trauma Stress Disord Treat. 2014;3(4). pii: 1000133.

39.

MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.

Shaham L, Vendramini E, Ge Y, Goren Y, Birger Y, Tijssen MR, McNulty M, Geron I, Schwartzman O, Goldberg L, Chou ST, Pitman H, Weiss MJ, Michaeli S, Sredni B, Göttgens B, Crispino JD, Taub JW, Izraeli S.

Blood. 2015 Feb 19;125(8):1292-301. doi: 10.1182/blood-2014-06-581892. Epub 2014 Dec 22. Erratum in: Blood. 2016 Apr 21;127(16):2042. Erratum in: Blood. 2016 Apr 21;127(16):2042.

40.

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.

Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L, Ge Y.

Cancer Lett. 2015 Jan 28;356(2 Pt B):656-68. doi: 10.1016/j.canlet.2014.10.015. Epub 2014 Oct 18.

41.

Down syndrome preleukemia and leukemia.

Maloney KW, Taub JW, Ravindranath Y, Roberts I, Vyas P.

Pediatr Clin North Am. 2015 Feb;62(1):121-37. doi: 10.1016/j.pcl.2014.09.009.

PMID:
25435116
42.

Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.

Hanmod SS, Wang G, Edwards H, Buck SA, Ge Y, Taub JW, Wang Z.

Pediatr Blood Cancer. 2015 Jan;62(1):52-9. doi: 10.1002/pbc.25232. Epub 2014 Oct 12.

PMID:
25308916
43.

Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.

Xie C, Edwards H, Caldwell JT, Wang G, Taub JW, Ge Y.

Mol Oncol. 2015 Feb;9(2):409-21. doi: 10.1016/j.molonc.2014.09.008. Epub 2014 Oct 2.

44.

Prognosis and management of acute myeloid leukemia in patients with Down syndrome.

Caldwell JT, Ge Y, Taub JW.

Expert Rev Hematol. 2014 Dec;7(6):831-40. doi: 10.1586/17474086.2014.959923. Epub 2014 Sep 18. Review.

45.

Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.

Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H.

Br J Haematol. 2015 Jan;168(1):94-101. doi: 10.1111/bjh.13107. Epub 2014 Aug 28.

46.

CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.

Qi W, Xie C, Li C, Caldwell JT, Edwards H, Taub JW, Wang Y, Lin H, Ge Y.

J Hematol Oncol. 2014 Aug 1;7:53. doi: 10.1186/s13045-014-0053-9.

47.

Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.

Caldwell JT, Edwards H, Buck SA, Ge Y, Taub JW.

Pediatr Blood Cancer. 2014 Oct;61(10):1767-73. doi: 10.1002/pbc.25081. Epub 2014 Jun 24.

48.

AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.

Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, Horton TM, Gamis AS, Meshinchi S, Loken MR, Razzouk BI.

Cancer. 2014 Aug 15;120(16):2482-9. doi: 10.1002/cncr.28674. Epub 2014 Apr 25.

49.

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.

Niu X, Wang G, Wang Y, Caldwell JT, Edwards H, Xie C, Taub JW, Li C, Lin H, Ge Y.

Leukemia. 2014 Jul;28(7):1557-60. doi: 10.1038/leu.2014.72. Epub 2014 Feb 17. No abstract available.

50.

Temperament, personality, and quality of life in pediatric cancer patients.

Harper FW, Goodlett BD, Trentacosta CJ, Albrecht TL, Taub JW, Phipps S, Penner LA.

J Pediatr Psychol. 2014 May;39(4):459-68. doi: 10.1093/jpepsy/jst141. Epub 2014 Jan 17.

Supplemental Content

Support Center